Tradestie Institutional Equity Comparison Engine
OBIO vs CVM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CVM Overall Edge
CVM Captures Institutional Edge (2โ2 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cel-Sci Corporation (CVM) driven by superior Valuation, Growth & Margin while OBIO counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, OBIO trades at N/M Forward P/E with -195.4% operating margin (-89.4% YoY revenue) versus CVM at 23.0x Forward P/E and 0.0% operating margin (-62.7% YoY). In options structure, OBIO sits in BREAKOUT (<1st %ile IV; Dealer Gamma Walls on Pro) against CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
CVM
OBIO N/M vs CVM 23.0x Fwd P/E
Growth & Margin Winner
CVM
Op Margin -195.4% vs 0.0% ยท YoY -89.4% vs -62.7%
Momentum & Technical Winner
OBIO
1Y +76.9% vs -73.8% ยท 52W Pos 88% vs 14%
Options & Structure Winner
OBIO
BREAKOUT (<1st %ile IV) vs BREAKDOWN (N/A IV)
OBIO
NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.97
-2.11% 1D
Market Cap
$570.6M
1M Return
+23.36%
1Y Return
+76.9%
Forward P/E
N/M
Unified AI Score
42.9 / 100
HOLD
Tech 15.0
Fund 40.0
Flow 62.0
Mom 44.0
CVM
NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.85
+11.45% 1D
Market Cap
$22.5M
1M Return
+12.12%
1Y Return
-73.76%
Forward P/E
23.0x
Unified AI Score
43.5 / 100
HOLD
Tech 23.0
Fund 47.0
Flow 50.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
OBIO +76.9%
CVM -73.76%
Spread: +148.95 pp (OBIO Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | OBIO Revenue | CVM Revenue | OBIO Op. Margin | CVM Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2011 | N/A | $0M | N/A | -1881.0% | CVM |
| FY2012 | N/A | $0M | N/A | -6772.3% | CVM |
| FY2013 | N/A | $0M | N/A | -12450.1% | CVM |
| FY2014 | N/A | $0M | N/A | -9721.4% | CVM |
| FY2022 | $0M | N/A | -924.3% | N/A | OBIO |
| FY2023 | $0M | N/A | -1866.2% | N/A | OBIO |
| FY2024 | $0M | N/A | -2437.5% | N/A | OBIO |
| FY2025 | $30M | N/A | -154.7% | N/A | OBIO |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | OBIO | CVM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $570.6M | $22.5M | Larger Scale | OBIO |
| Trailing P/E Ratio Valuation | N/M | 23.0x | Lower Multiple | CVM |
| Forward P/E Ratio Valuation | N/M | 23.0x | Lower Multiple | CVM |
| Revenue Growth (YoY) Growth | -89.4% | -62.7% | Higher Growth | CVM |
| Operating Margin (TTM) Profitability | -195.4% | 0.0% | Higher Margin | CVM |
| Net Profit Margin Profitability | -182.5% | 0.0% | Higher Margin | CVM |
| Return on Equity (ROE) Capital Efficiency | -182.3% | -252.5% | Higher ROE | OBIO |
| 52-Week Range Position Momentum | 88% ($3โ$7) | 14% ($1โ$8) | Stronger Trend | OBIO |
| Beta / 30D Volatility Risk Regime | 1.16ฮฒ ยท 80% Vol | 0.42ฮฒ ยท 140% Vol | Lower Realized Risk | OBIO |
| Unified Institutional Score Composite Signal | 42.9 / 100 (HOLD) | 43.5 / 100 (HOLD) | Higher Composite | CVM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full OBIO vs CVM Buy Guide
OBIO
BREAKOUT
33d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
CVM
BREAKDOWN
29d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither OBIO nor CVM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.